There’s a need in secondary prevention for personalized risk estimates to motivate patients and guide care, researchers say.
Polypills for HFrEF are being tested in RCTs, and if they’re approved, experts want to be ready for their rollout and use.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback